<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31540330</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>18</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Enhanced Function and Overexpression of Metabotropic Glutamate Receptors 1 and 5 in the Spinal Cord of the SOD1<sup>G93A</sup> Mouse Model of Amyotrophic Lateral Sclerosis during Disease Progression.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4552</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms20184552</ELocationID><Abstract><AbstractText>Glutamate (Glu)-mediated excitotoxicity is a major cause of amyotrophic lateral sclerosis (ALS) and our previous work highlighted that abnormal Glu release may represent a leading mechanism for excessive synaptic Glu. We demonstrated that group I metabotropic Glu receptors (mGluR1, mGluR5) produced abnormal Glu release in SOD1<sup>G93A</sup> mouse spinal cord at a late disease stage (120 days). Here, we studied this phenomenon in pre-symptomatic (30 and 60 days) and early-symptomatic (90 days) SOD1<sup>G93A</sup> mice. The mGluR1/5 agonist (<i>S</i>)-3,5-Dihydroxyphenylglycine (3,5-DHPG) concentration dependently stimulated the release of [<sup>3</sup>H]d-Aspartate ([<sup>3</sup>H]d-Asp), which was comparable in 30- and 60-day-old wild type mice and SOD1<sup>G93A</sup> mice. At variance, [<sup>3</sup>H]d-Asp release was significantly augmented in 90-day-old SOD1<sup>G93A</sup> mice and both mGluR1 and mGluR5 were involved. The 3,5-DHPG-induced [<sup>3</sup>H]d-Asp release was exocytotic, being of vesicular origin and mediated by intra-terminal Ca<sup>2+</sup> release. mGluR1 and mGluR5 expression was increased in Glu spinal cord axon terminals of 90-day-old SOD1<sup>G93A</sup> mice, but not in the whole axon terminal population. Interestingly, mGluR1 and mGluR5 were significantly augmented in total spinal cord tissue already at 60 days. Thus, function and expression of group I mGluRs are enhanced in the early-symptomatic SOD1<sup>G93A</sup> mouse spinal cord, possibly participating in excessive Glu transmission and supporting their implication in ALS. Please define all abbreviations the first time they appear in the abstract, the main text, and the first figure or table caption.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonifacino</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Unit of Pharmacology and Toxicology, University of Genoa, 16148 Genova, Italy. bonifacino@difar.unige.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rebosio</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Unit of Pharmacology and Toxicology, University of Genoa, 16148 Genova, Italy. claudiarebosio@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Provenzano</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Unit of Pharmacology and Toxicology, University of Genoa, 16148 Genova, Italy. provenzano.phd@difar.unige.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torazza</LastName><ForeName>Carola</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Unit of Pharmacology and Toxicology, University of Genoa, 16148 Genova, Italy. torazza@difar.unige.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balbi</LastName><ForeName>Matilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Unit of Pharmacology and Toxicology, University of Genoa, 16148 Genova, Italy. balbi.phd@difar.unige.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milanese</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Unit of Pharmacology and Toxicology and Center of Excellence for Biomedical Research (CEBR), University of Genoa, 16132 Genova, Italy. milanese@difar.unige.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raiteri</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Unit of Pharmacology and Toxicology and Center of Excellence for Biomedical Research (CEBR), University of Genoa, 16132 Genova, Italy. lraiter@difar.unige.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Usai</LastName><ForeName>Cesare</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8863-7759</Identifier><AffiliationInfo><Affiliation>Institute of Biophysics, National Research Council (CNR), 16149 Genova, Italy. usai@ge.ibf.cnr.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fedele</LastName><ForeName>Ernesto</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0386-0925</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Unit of Pharmacology and Toxicology and Center of Excellence for Biomedical Research (CEBR), University of Genoa, 16132 Genova, Italy. fedele@difar.unige.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, 16132 Genova, Italy. fedele@difar.unige.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonanno</LastName><ForeName>Giambattista</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3744-5786</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Unit of Pharmacology and Toxicology and Center of Excellence for Biomedical Research (CEBR), University of Genoa, 16132 Genova, Italy. bonanno@difar.unige.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, 16132 Genova, Italy. bonanno@difar.unige.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RBSI14B1Z1</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>2018.AAI629.U730/SD/pv</GrantID><Agency>Compagnia di San Paolo</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578936">Grm5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064529">Receptor, Metabotropic Glutamate 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018094">Receptors, Metabotropic Glutamate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012118">Resorcinols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C104077">metabotropic glutamate receptor type 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>5YR2N37E6D</RegistryNumber><NameOfSubstance UI="C079215">3,5-dihydroxyphenylglycine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>TE7660XO1C</RegistryNumber><NameOfSubstance UI="D005998">Glycine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005998" MajorTopicYN="N">Glycine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064529" MajorTopicYN="N">Receptor, Metabotropic Glutamate 5</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018094" MajorTopicYN="N">Receptors, Metabotropic Glutamate</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012118" MajorTopicYN="N">Resorcinols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SOD1G93A mice</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">disease progression</Keyword><Keyword MajorTopicYN="N">glutamate release</Keyword><Keyword MajorTopicYN="N">mGluR1/mGluR5 expression</Keyword><Keyword MajorTopicYN="N">metabotropic glutamate receptor 1 (mGluR1)</Keyword><Keyword MajorTopicYN="N">metabotropic glutamate receptor 5 (mGluR5)</Keyword><Keyword MajorTopicYN="N">spinal cord</Keyword></KeywordList><CoiStatement>The authors have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31540330</ArticleId><ArticleId IdType="pmc">PMC6774337</ArticleId><ArticleId IdType="doi">10.3390/ijms20184552</ArticleId><ArticleId IdType="pii">ijms20184552</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown R.H., Jr. Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice. Cell. 1995;80:687&#x2013;692. doi: 10.1016/0092-8674(95)90346-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(95)90346-1</ArticleId><ArticleId IdType="pubmed">7889564</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Rademakers R., Roeber S., Baker M., Kretzschmar H.A., Mackenzie I.R. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132:2922&#x2013;2931. doi: 10.1093/brain/awp214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp214</ArticleId><ArticleId IdType="pmc">PMC2768659</ArticleId><ArticleId IdType="pubmed">19674978</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M., Bede P., Byrne S., Jordan N., Gallagher L., Wynne B., O&#x2019;Brien C., Phukan J., Lynch C., Pender N., et al. Cognitive changes predict functional decline in ALS: A population-based longitudinal study. Neurology. 2013;80:1590&#x2013;1597. doi: 10.1212/WNL.0b013e31828f18ac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828f18ac</ArticleId><ArticleId IdType="pubmed">23553481</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B., Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2014;10:661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., Van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H., Le W.D., Xie Y.Y., Wang X.P. Current Therapy of Drugs in Amyotrophic Lateral Sclerosis. Curr. Neuropharmacol. 2016;14:314&#x2013;321. doi: 10.2174/1570159X14666160120152423.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X14666160120152423</ArticleId><ArticleId IdType="pmc">PMC4876587</ArticleId><ArticleId IdType="pubmed">26786249</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Aoki M., Tsuji S., Itoyama Y., Sobue G., Togo M., Hamada C., Tanaka M., Akimoto M., Nakamura K., et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Chi&#xf2; A., Traynor B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17:17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli E.T., Lasseigne B.N., Petrovski S., Sapp P.C., Dion P.A., Leblond C.S., Couthouis J., Lu Y.F., Wang Q., Krueger B.J., et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436&#x2013;1441. doi: 10.1126/science.aaa3650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa3650</ArticleId><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Battistini S., Calvo A., Caponnetto C., Conforti F.L., Corbo M., Giannini F., Mandrioli J., Mora G., Sabatelli M., et al. Genetic counselling in ALS: Facts, uncertainties and clinical suggestions. J. Neurol. Neurosurg. Psychiatry. 2014;85:478&#x2013;485. doi: 10.1136/jnnp-2013-305546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-305546</ArticleId><ArticleId IdType="pubmed">23833266</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland D.W., Bruijn L.I., Wong P.C., Marszalek J.R., Vechio J.D., Lee M.K., Xu X.S., Borchelt D.R., Sisodia S.S., Price D.L. Mechanisms of selective motorneuron death in transgenic mouse models of motorneuron disease. Neurology. 1996;47:S54&#x2013;S61. doi: 10.1212/WNL.47.4_Suppl_2.54S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.4_Suppl_2.54S</ArticleId><ArticleId IdType="pubmed">8858052</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison B.M., Morrison J.H. Amyotrophic lateral sclerosis associated with mutations in superoxide dismutase: A putative mechanism of degeneration. Brain Res. Rev. 1999;29:121&#x2013;135. doi: 10.1016/S0165-0173(98)00049-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0173(98)00049-6</ArticleId><ArticleId IdType="pubmed">9974153</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L., Kirby J., Grierson A.J., Sendtner M., Shaw P.J. Molecular pathways of motorneuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011;7:616&#x2013;630. doi: 10.1038/nrneurol.2011.152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.152</ArticleId><ArticleId IdType="pubmed">22051914</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijssen J., Comley L.H., Hedlund E. Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133:863&#x2013;885. doi: 10.1007/s00401-017-1708-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1708-8</ArticleId><ArticleId IdType="pmc">PMC5427160</ArticleId><ArticleId IdType="pubmed">28409282</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and progression in inherited ALS determined by motorneurons and microglia. Science. 2006;312:1389&#x2013;1392. doi: 10.1126/science.1123511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009;187:761&#x2013;772. doi: 10.1083/jcb.200908164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200908164</ArticleId><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips A.M., Hester M.E., Miranda C.J., Meyer K., Braun L., Frakes A., Song S., Likhite S., Murtha M.J., Foust K.D., et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 2011;29:824&#x2013;828. doi: 10.1038/nbt.1957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1957</ArticleId><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P.J., Forrest V., Ince P.G., Richardson J.P., Wastell H.J. CSF and plasma amino acid levels in motorneuron disease: Elevation of CSF glutamate in a subset of patients. Neurodegeneration. 1995;4:209&#x2013;216. doi: 10.1006/neur.1995.0026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/neur.1995.0026</ArticleId><ArticleId IdType="pubmed">7583686</ArticleId></ArticleIdList></Reference><Reference><Citation>Spreux-Varoquaux O., Bensimon G., Lacomblez L., Salachas F., Pradat P.F., Le Forestier N., Marouan A., Dib M., Meininger V. Glutamate levels in cerebro spinal fluid in amyotrophic lateral sclerosis: A reppraisal using a new HPLC method with coulometric detection in a large cohort of patients. J. Neurol. Sci. 2002;193:73&#x2013;78. doi: 10.1016/S0022-510X(01)00661-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00661-X</ArticleId><ArticleId IdType="pubmed">11790386</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A., Moritz T., Marklund S.L., Antti H., Andersen P.M. Disease-related changes in the cerebro spinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS. PLoS ONE. 2011;6:e17947. doi: 10.1371/journal.pone.0017947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0017947</ArticleId><ArticleId IdType="pmc">PMC3070699</ArticleId><ArticleId IdType="pubmed">21483737</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D., Van Kammen M., Levey A.I., Martin L.J., Kuncl R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 1995;38:73&#x2013;84. doi: 10.1002/ana.410380114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410380114</ArticleId><ArticleId IdType="pubmed">7611729</ArticleId></ArticleIdList></Reference><Reference><Citation>Maragakis N.J., Dykes-Hoberg M., Rothstein J.D. Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann. Neurol. 2004;55:469&#x2013;477. doi: 10.1002/ana.20003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20003</ArticleId><ArticleId IdType="pubmed">15048885</ArticleId></ArticleIdList></Reference><Reference><Citation>Foran E., Bogush A., Goffredo M., Roncaglia P., Gustincich S., Pasinelli P., Trotti D. Motor neuron impairment mediated by a sumoylated fragment of the glial glutamate transporter EAAT2. Glia. 2011;59:1719&#x2013;1731. doi: 10.1002/glia.21218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.21218</ArticleId><ArticleId IdType="pmc">PMC3896305</ArticleId><ArticleId IdType="pubmed">21769946</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., Mavel S., Corcia P., Gordon P.H. The glutamate hypothesis in ALS: Pathophysiology and drug development. Curr. Med. Chem. 2014;21:3551&#x2013;3575. doi: 10.2174/0929867321666140916120118.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867321666140916120118</ArticleId><ArticleId IdType="pubmed">25245510</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanese M., Zappettini S., Onofri F., Musazzi L., Tardito D., Bonifacino T., Messa M., Racagni G., Usai C., Benfenati F., et al. Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2011;116:1028&#x2013;1042. doi: 10.1111/j.1471-4159.2010.07155.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.07155.x</ArticleId><ArticleId IdType="pubmed">21175617</ArticleId></ArticleIdList></Reference><Reference><Citation>Giribaldi F., Milanese M., Bonifacino T., Rossi P.I.A., Di Prisco S., Pittaluga A., Tacchetti C., Puliti A., Usai C., Bonanno G. Group I metabotropic glutamate autoreceptors induce abnormal glutamate exocytosis in a mouse model of amyotrophic lateral sclerosis. Neuropharmacology. 2013;66:253&#x2013;263. doi: 10.1016/j.neuropharm.2012.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2012.05.018</ArticleId><ArticleId IdType="pubmed">22634363</ArticleId></ArticleIdList></Reference><Reference><Citation>Raiteri L., Paolucci E., Prisco S., Raiteri M., Bonanno G. Activation of a glycine transporter on spinal cord neurons causes enhanced glutamate release in a mouse model of amyotrophic lateral sclerosis. Br. J. Pharmacol. 2003;138:1021&#x2013;1025. doi: 10.1038/sj.bjp.0705142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0705142</ArticleId><ArticleId IdType="pmc">PMC1573752</ArticleId><ArticleId IdType="pubmed">12684256</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanese M., Zappettini S., Jacchetti E., Bonifacino T., Cervetto C., Usai C., Bonanno G. In vitro activation of GAT1 transporters expressed in spinal cord gliosomes stimulates glutamate release that is abnormally elevated in the SOD1/G93A(+) mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2010;113:489&#x2013;501. doi: 10.1111/j.1471-4159.2010.06628.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06628.x</ArticleId><ArticleId IdType="pubmed">20132478</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanese M., Bonifacino T., Fedele E., Rebosio C., Cattaneo L., Benfenati F., Usai C., Bonanno G. Exocytosis regulates trafficking of GABA and glycine heterotransporters in spinal cord glutamatergic synapses: A mechanism for the excessive heterotransporter-induced release of glutamate in experimental amyotrophic lateral sclerosis. Neurobiol. Dis. 2015;74:314&#x2013;324. doi: 10.1016/j.nbd.2014.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.12.004</ArticleId><ArticleId IdType="pubmed">25497732</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Raiteri L., Stigliani S., Zappettini S., Mercuri N.B., Raiteri M., Bonanno G. Excessive and precocious glutamate release in a mouse model of amyotrophic lateral sclerosis. Neuropharmacology. 2004;46:782&#x2013;792. doi: 10.1016/j.neuropharm.2003.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2003.11.025</ArticleId><ArticleId IdType="pubmed">15033338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino T., Musazzi L., Milanese M., Seguini M., Marte A., Gallia E., Cattaneo L., Onofri F., Popoli M., Bonanno G. Altered mechanisms underlying the abnormal glutamate release in amyotrophic lateral sclerosis at a pre-symptomatic stage of the disease. Neurobiol. Dis. 2016;95:122&#x2013;133. doi: 10.1016/j.nbd.2016.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.07.011</ArticleId><ArticleId IdType="pubmed">27425885</ArticleId></ArticleIdList></Reference><Reference><Citation>Wi&#x15b;niewski K., Car H. (S)-3,5-DHPG: A review. CNS Drug Rev. 2002;8:101&#x2013;116. doi: 10.1111/j.1527-3458.2002.tb00218.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1527-3458.2002.tb00218.x</ArticleId><ArticleId IdType="pmc">PMC6741645</ArticleId><ArticleId IdType="pubmed">12070529</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruno V., Battaglia G., Kingston A., O&#x2019;Neill M.J., Catania M.V., Di Grezia R., Nicoletti F. Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): Comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology. 1999;38:199&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">10218860</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini F., Lingenh&#xf6;hl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., Biollaz M., Allgeier H., Heckendorn R., Urwyler S., et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology. 1999;38:1493&#x2013;1503. doi: 10.1016/S0028-3908(99)00082-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0028-3908(99)00082-9</ArticleId><ArticleId IdType="pubmed">10530811</ArticleId></ArticleIdList></Reference><Reference><Citation>Pin J.P., Acher F. The metabotropic glutamate receptors: Structure, activation mechanism and pharmacology. Curr. Drug Targets CNS Neurol. Disord. 2002;1:297&#x2013;317. doi: 10.2174/1568007023339328.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568007023339328</ArticleId><ArticleId IdType="pubmed">12769621</ArticleId></ArticleIdList></Reference><Reference><Citation>Malgaroli A., Meldolesi J. [Ca2+]i oscillations from internal stores sustain exocytic secretion from the chromaffin cells of the rat. FEBS Lett. 1991;283:169&#x2013;172. doi: 10.1016/0014-5793(91)80580-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(91)80580-V</ArticleId><ArticleId IdType="pubmed">2044755</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleasdale J.E., Thakur N.R., Gremban R.S., Bundy G.L., Fitzpatrick F.A., Smith R.J., Bunting S. Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J. Pharmacol. Exp. 1990;255:756&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">2147038</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama T., Kanaji T., Nakade S., Kanno T., Mikoshiba K. 2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins (1,4,5)P3-induced Ca2+ release. J. Biochem. 1997;122:498&#x2013;505. doi: 10.1093/oxfordjournals.jbchem.a021780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.jbchem.a021780</ArticleId><ArticleId IdType="pubmed">9348075</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman E.J., Siebers A., Altendorf K. Bafilomycins: A class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc. Natl. Acad. Sci. USA. 1988;85:7972&#x2013;7976. doi: 10.1073/pnas.85.21.7972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.85.21.7972</ArticleId><ArticleId IdType="pmc">PMC282335</ArticleId><ArticleId IdType="pubmed">2973058</ArticleId></ArticleIdList></Reference><Reference><Citation>Biber K., Laurie D.J., Berthele A., Sommer B., T&#xf6;lle T.R., Gebicke-H&#xe4;rter P.J., Van Calker D., Boddeke H.W. Expression and signalling of group I metabotropic glutamate receptors in astrocytes and microglia. J. Neurochem. 1999;72:1671&#x2013;1680. doi: 10.1046/j.1471-4159.1999.721671.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1999.721671.x</ArticleId><ArticleId IdType="pubmed">10098876</ArticleId></ArticleIdList></Reference><Reference><Citation>Luyt K., Varadi A., Molnar E. Functional metabotropic glutamate receptors are expressed in oligodendrocyte progenitor cells. J. Neurochem. 2003;84:1452&#x2013;1464. doi: 10.1046/j.1471-4159.2003.01661.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.01661.x</ArticleId><ArticleId IdType="pubmed">12614345</ArticleId></ArticleIdList></Reference><Reference><Citation>Panatier A., Robitaille R. Astrocytic mGluR5 and the tripartite synapse. Neuroscience. 2016;323:29&#x2013;34. doi: 10.1016/j.neuroscience.2015.03.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.03.063</ArticleId><ArticleId IdType="pubmed">25847307</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoletti F., Bockaert J., Collingridge G.L., Conn P.J., Ferraguti F., Schoepp D.D., Wroblewski J.T., Pin J.P. Metabotropic glutamate receptors: From the work bench to the bedside. Neuropharmacology. 2011;60:1017&#x2013;1041. doi: 10.1016/j.neuropharm.2010.10.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2010.10.022</ArticleId><ArticleId IdType="pmc">PMC3787883</ArticleId><ArticleId IdType="pubmed">21036182</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronica E., Catania M.V., Geurts J., Yankaya B., Troost D. Immuno-histochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: Upregulation in reactive astrocytes. Neuroscience. 2001;105:509&#x2013;520. doi: 10.1016/S0306-4522(01)00181-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(01)00181-6</ArticleId><ArticleId IdType="pubmed">11672616</ArticleId></ArticleIdList></Reference><Reference><Citation>Martorana F., Brambilla L., Valori C.F., Bergamaschi C., Roncoroni C., Aronica E., Volterra A., Bezzi P., Rossi D. The BH4 domain of Bcl-X(L) rescues astrocyte degeneration in amyotrophic lateral sclerosis by modulating intracellular calcium signals. Hum. Mol. Genet. 2012;21:826&#x2013;840. doi: 10.1093/hmg/ddr513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr513</ArticleId><ArticleId IdType="pubmed">22072391</ArticleId></ArticleIdList></Reference><Reference><Citation>Anneser J.M., Ince P.G., Shaw P.J., Borasio G.D. Differential expression of mGluR5 in human lumbosacral motoneurons. Neuroreport. 2004;15:271&#x2013;273. doi: 10.1097/00001756-200402090-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200402090-00012</ArticleId><ArticleId IdType="pubmed">15076751</ArticleId></ArticleIdList></Reference><Reference><Citation>Anneser J.M., Chahli C., Ince P.G., Borasio G.D., Shaw P.J. Glial proliferation and metabotropic glutamate receptor expression in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2004;63:831&#x2013;840. doi: 10.1093/jnen/63.8.831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/63.8.831</ArticleId><ArticleId IdType="pubmed">15330338</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D., Brambilla L., Valori C.F., Roncoroni C., Crugnola A., Yokota T., Bredesen D.E., Volterra A. Focal degeneration of astrocytes in amyotrophic lateral sclerosis. Cell Death Differ. 2008;15:1691&#x2013;1700. doi: 10.1038/cdd.2008.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2008.99</ArticleId><ArticleId IdType="pubmed">18617894</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergouts M., Doyen P.J., Peeters M., Opsomer R., Hermans E. Constitutive downregulation protein kinase C epsilon in hSOD1G93A astrocytes influences mGluR5 signaling and the regulation of glutamate uptake. Glia. 2018;66:749&#x2013;761. doi: 10.1002/glia.23279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23279</ArticleId><ArticleId IdType="pubmed">29266405</ArticleId></ArticleIdList></Reference><Reference><Citation>Musante V., Neri E., Feligioni M., Puliti A., Pedrazzi M., Conti V., Usai C., Diaspro A., Ravazzolo R., Henley J.M., et al. Presynaptic mGlu1 and mGlu5 autoreceptors facilitate glutamate exocytosis from mouse cortical nerve endings. Neuropharmacology. 2008;55:474&#x2013;482. doi: 10.1016/j.neuropharm.2008.06.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2008.06.056</ArticleId><ArticleId IdType="pmc">PMC3310906</ArticleId><ArticleId IdType="pubmed">18625255</ArticleId></ArticleIdList></Reference><Reference><Citation>Doumazane E., Scholler P., Zwier J.M., Trinquet E., Rondard P., Pin J.P. A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors. FASEB J. 2011;25:66&#x2013;77. doi: 10.1096/fj.10-163147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.10-163147</ArticleId><ArticleId IdType="pubmed">20826542</ArticleId></ArticleIdList></Reference><Reference><Citation>Stifanese R., Averna M., De Tullio R., Pedrazzi M., Beccaria F., Salamino F., Milanese M., Bonanno G., Pontremoli S., Melloni E. Adaptive modifications in the calpain/calpastatin system in brain cells after persistent alteration in Ca2+ homeostasis. J. Biol. Chem. 2010;285:631&#x2013;643. doi: 10.1074/jbc.M109.031674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.031674</ArticleId><ArticleId IdType="pmc">PMC2804211</ArticleId><ArticleId IdType="pubmed">19880516</ArticleId></ArticleIdList></Reference><Reference><Citation>Stifanese R., Averna M., De Tullio R., Pedrazzi M., Milanese M., Bonifacino T., Bonanno G., Salamino F., Pontremoli S., Melloni E. Role of calpain-1 in the early phase of experimental ALS. Arch. Biochem. Biophys. 2014;562:1&#x2013;8. doi: 10.1016/j.abb.2014.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2014.08.006</ArticleId><ArticleId IdType="pubmed">25151305</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans J.S., Turner M.D. Emerging functions of the calpain superfamily of cysteine proteases in neuroendocrine secretory pathways. J. Neurochem. 2007;103:849&#x2013;859. doi: 10.1111/j.1471-4159.2007.04815.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04815.x</ArticleId><ArticleId IdType="pubmed">17666040</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonanno G., Raiteri M. Release-regulating presynaptic heterocarriers. Prog. Neurobiol. 1994;44:451&#x2013;462. doi: 10.1016/0301-0082(94)90006-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0301-0082(94)90006-X</ArticleId><ArticleId IdType="pubmed">7886234</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Prisco S., Merega E., Milanese M., Summa M., Casazza S., Raffaghello L., Pistoia V., Uccelli A., Pittaluga A. CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice. Neuropharmacology. 2013;75:337&#x2013;346. doi: 10.1016/j.neuropharm.2013.07.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2013.07.037</ArticleId><ArticleId IdType="pubmed">23958452</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheefhals N., MacGillavry H.D. Functional organization of postsynaptic glutamate receptors. Mol. Cell. Neurosci. 2018;91:82&#x2013;94. doi: 10.1016/j.mcn.2018.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2018.05.002</ArticleId><ArticleId IdType="pmc">PMC6276983</ArticleId><ArticleId IdType="pubmed">29777761</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Antoni S., Berretta A., Bonaccorso C.M., Bruno V., Aronica E., Nicoletti F., Catania M.V. Metabotropic glutamate receptors in glial cells. Neurochem. Res. 2008;33:2436&#x2013;2443. doi: 10.1007/s11064-008-9694-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-008-9694-9</ArticleId><ArticleId IdType="pubmed">18438710</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Takahashi R., Misawa H., Cleveland D.W. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008;11:251&#x2013;253. doi: 10.1038/nn2047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2047</ArticleId><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes A.E., Ferraiuolo L., Haidet-Phillips A.M., Schmelzer L., Braun L., Miranda C.J., Ladner K.J., Bevan A.K., Foust K.D., Godbout J.P., et al. Microglia induce motor neuron death via the classical NF-&#x3ba;B pathway in amyotrophic lateral sclerosis. Neuron. 2014;81:1009&#x2013;1023. doi: 10.1016/j.neuron.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonneman A., Robberecht W., Van Den Bosch L. The role of oligodendroglial dysfunction in amyotrophic lateral sclerosis. Neurodegener Dis. Manag. 2014;4:223&#x2013;239. doi: 10.2217/nmt.14.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt.14.21</ArticleId><ArticleId IdType="pubmed">25095817</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L., Meyer K., Sherwood T.W., Vick J., Likhite S., Frakes A., Miranda C.J., Braun L., Heath P.R., Pineda R., et al. Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proc. Natl. Acad. Sci. USA. 2016;113:E6496&#x2013;E6505. doi: 10.1073/pnas.1607496113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1607496113</ArticleId><ArticleId IdType="pmc">PMC5081600</ArticleId><ArticleId IdType="pubmed">27688759</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanese M., Giribaldi F., Melone M., Bonifacino T., Musante I., Carminati E., Rossi P.I., Vergani L., Voci A., Conti F., et al. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2014;64:48&#x2013;59. doi: 10.1016/j.nbd.2013.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.11.006</ArticleId><ArticleId IdType="pubmed">24361555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino T., Cattaneo L., Gallia E., Puliti A., Melone M., Provenzano F., Bossi S., Musante I., Usai C., Conti F., et al. In-vivo effects of knocking-down metabotropic glutamate receptor 5 in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neuropharmacology. 2017;123:433&#x2013;445. doi: 10.1016/j.neuropharm.2017.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2017.06.020</ArticleId><ArticleId IdType="pubmed">28645622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino T., Provenzano F., Gallia E., Ravera S., Torazza C., Bossi S., Ferrando S., Puliti A., Van den Bosch L., Bonanno G., et al. In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2019;129:79&#x2013;92. doi: 10.1016/j.nbd.2019.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.05.007</ArticleId><ArticleId IdType="pubmed">31102766</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzi M., Benarese M., Boroni F., Goffi F., Valerio A., Spano P.F. Neuroprotection by metabotropic glutamate receptor agonists on kainate-induced degeneration of motor neurons in spinal cord slices from adult rat. Neuropharmacology. 2000;39:903&#x2013;910. doi: 10.1016/S0028-3908(99)00257-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0028-3908(99)00257-9</ArticleId><ArticleId IdType="pubmed">10699456</ArticleId></ArticleIdList></Reference><Reference><Citation>Anneser J.M., Chahli C., Borasio G.D. Protective effect of metabotropic glutamate receptor inhibition on amyotrophic lateral sclerosis-cerebrospinal fluid toxicity in vitro. Neuroscience. 2006;141:1879&#x2013;1886. doi: 10.1016/j.neuroscience.2006.05.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2006.05.044</ArticleId><ArticleId IdType="pubmed">16820266</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Antoni S., Berretta A., Seminara G., Longone P., Giuffrida-Stella A.M., Battaglia G., Sortino M.A., Nicoletti F., Catania M.V. A prolonged pharmacological blockade of type-5 metabotropic glutamate receptors protects cultured spinal cord motorneurons against excitotoxic death. Neurobiol. Dis. 2011;42:252&#x2013;264. doi: 10.1016/j.nbd.2011.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.01.013</ArticleId><ArticleId IdType="pubmed">21232601</ArticleId></ArticleIdList></Reference><Reference><Citation>Montana M.C., Cavallone L.F., Stubbert K.K., Stefanescu A.D., Kharasch E.D., Gereau R.W. The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine. J. Pharmacol. Exp. Ther. 2009;330:834&#x2013;843. doi: 10.1124/jpet.109.154138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.109.154138</ArticleId><ArticleId IdType="pmc">PMC2729799</ArticleId><ArticleId IdType="pubmed">19515968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindemann L., Jaeschke G., Michalon A., Vieira E., Honer M., Spooren W., Porter R., Hartung T., Kolczewski S., B&#xfc;ttelmann B., et al. CTEP: A novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J. Pharmacol. Exp. Ther. 2011;339:474&#x2013;486. doi: 10.1124/jpet.111.185660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.111.185660</ArticleId><ArticleId IdType="pubmed">21849627</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenga J., Hayashi S., De Vrij F.M., Koekkoek S.K., Van der Linde H.C., Nieuwenhuizen I., Song C., Buijsen R.A., Pop A.S., Gomezmancilla B., et al. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol. Dis. 2011;42:311&#x2013;317. doi: 10.1016/j.nbd.2011.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.01.022</ArticleId><ArticleId IdType="pubmed">21316452</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalon A., Bruns A., Risterucci C., Honer M., Ballard T.M., Ozmen L., Jaeschke G., Wettstein J.G., Von Kienlin M., K&#xfc;nnecke B., et al. Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice. Biol. Psychiatry. 2014;75:189&#x2013;197. doi: 10.1016/j.biopsych.2013.05.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2013.05.038</ArticleId><ArticleId IdType="pubmed">23910948</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterlik D., Stangl C., Bauer A., Bludau A., Keller J., Grabski D., Killian T., Schmidt D., Zajicek F., Jaeschke G., et al. Blocking metabotropic glutamate receptor subtype 5 relieves maladaptive chronic stress consequences. Brain Behav. Immun. 2017;59:79&#x2013;92. doi: 10.1016/j.bbi.2016.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2016.08.007</ArticleId><ArticleId IdType="pubmed">27524668</ArticleId></ArticleIdList></Reference><Reference><Citation>Abd-Elrahman K.S., Hamilton A., Vasefi M., Ferguson S.S.G. Autophagy is increased following either pharmacological or genetic silencing of mGluR5 signaling in Alzheimer&#x2019;s disease mouse models. Mol. Brain. 2018;11:19. doi: 10.1186/s13041-018-0364-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-018-0364-9</ArticleId><ArticleId IdType="pmc">PMC5892040</ArticleId><ArticleId IdType="pubmed">29631635</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter R.H., Jaeschke G., Spooren W., Ballard T.M., B&#xfc;ttelmann B., Kolczewski S., Peters J.U., Prinssen E., Wichmann J., Vieira E., et al. Fenobam: A clinically validated non-benzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 2005;315:711&#x2013;721. doi: 10.1124/jpet.105.089839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.105.089839</ArticleId><ArticleId IdType="pubmed">16040814</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry-Kravis E., Hessl D., Coffey S., Hervey C., Schneider A., Yuhas J., Hutchison J., Snape M., Tranfaglia M., Nguyen D.V., et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet. 2009;46:266&#x2013;271. doi: 10.1136/jmg.2008.063701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2008.063701</ArticleId><ArticleId IdType="pmc">PMC2658751</ArticleId><ArticleId IdType="pubmed">19126569</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindemann L., Porter R.H., Scharf S.H., Kuennecke B., Bruns A., Von Kienlin M., Harrison A.C., Paehler A., Funk C., Gloge A., et al. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. J. Pharmacol. Exp. Ther. 2015;353:213&#x2013;233. doi: 10.1124/jpet.114.222463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.114.222463</ArticleId><ArticleId IdType="pubmed">25665805</ArticleId></ArticleIdList></Reference><Reference><Citation>Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680&#x2013;685. doi: 10.1038/227680a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/227680a0</ArticleId><ArticleId IdType="pubmed">5432063</ArticleId></ArticleIdList></Reference><Reference><Citation>Raiteri L., Stigliani S., Usai C., Diaspro A., Paluzzi S., Milanese M., Raiteri M., Bonanno G. Functional expression of release-regulating glycine transporters GLYT1 on GABAergic neurons and GLYT2 on astrocytes in mouse spinal cord. Neurochem. Int. 2008;52:103&#x2013;112. doi: 10.1016/j.neuint.2007.04.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2007.04.027</ArticleId><ArticleId IdType="pubmed">17597258</ArticleId></ArticleIdList></Reference><Reference><Citation>Carney K.E., Milanese M., Van Nierop P., Li K.W., Oliet S.H.R., Smit A.B., Bonanno G., Verheijen M.H.G. Proteomic analysis of gliosomes from mouse brain: Identification and investigation of glial membrane proteins. J. Proteome Res. 2014;13:5918&#x2013;5927. doi: 10.1021/pr500829z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr500829z</ArticleId><ArticleId IdType="pubmed">25308431</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dyebinding. Anal. Biochem. 1976;72:248&#x2013;254. doi: 10.1016/0003-2697(76)90527-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-2697(76)90527-3</ArticleId><ArticleId IdType="pubmed">942051</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleck M.W., Barrionuevo G., Palmer A.M. Synaptosomal and vesicular accumulation of L-glutamate, L-aspartate and D-aspartate. Neurochem. Int. 2001;39:217&#x2013;225. doi: 10.1016/S0197-0186(01)00018-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-0186(01)00018-3</ArticleId><ArticleId IdType="pubmed">11434980</ArticleId></ArticleIdList></Reference><Reference><Citation>Raiteri L., Zappettini S., Milanese M., Fedele E., Raiteri M., Bonanno G. Mechanisms of glutamate release elicited in rat cerebrocortical nerve endings by &#x2018;pathologically&#x2019; elevated extraterminal K+ concentrations. J. Neurochem. 2007;103:952&#x2013;961. doi: 10.1111/j.1471-4159.2007.04784.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04784.x</ArticleId><ArticleId IdType="pubmed">17662048</ArticleId></ArticleIdList></Reference><Reference><Citation>Raiteri M., Bonanno G., Marchi M., Maura G. Is there a functional linkage between neurotransmitter uptake mechanisms and presynaptic receptors? J. Pharmacol. Exp. Ther. 1984;231:671&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">6150107</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossi S., Musante I., Bonfiglio T., Bonifacino T., Emionite L., Cerminara M., Cervetto C., Marcoli M., Bonanno G., Ravazzolo R., et al. Genetic inactivation of mGlu5 receptor improves motor coordination in the Grm1crv4 mouse model of SCAR13 ataxia. Neurobiol. Dis. 2018;109:44&#x2013;53. doi: 10.1016/j.nbd.2017.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2017.10.001</ArticleId><ArticleId IdType="pubmed">28982591</ArticleId></ArticleIdList></Reference><Reference><Citation>Manders E.M., Stap J., Brakenhoff G.J., Van Driel R., Aten J.A. Dynamics of three-dimensional replication patterns during the S-phase, analysed by double labelling of DNA and confocal microscopy. J. Cell Sci. 1992;103:857&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">1478975</ArticleId></ArticleIdList></Reference><Reference><Citation>Grynkiewicz G., Poenie M., Tsien R.Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985;260:3440&#x2013;3450.</Citation><ArticleIdList><ArticleId IdType="pubmed">3838314</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>